Medically reviewed by the CION Oncology Team · Last reviewed June 2026
TNBC is a distinct subtype of breast cancer that requires a different approach from other breast cancers. At CION, a dedicated tumor board of medical, surgical, and radiation oncologists reviews every TNBC case together — so your plan is built on the full picture, not one doctor's view.
*1-year survival, ICMR/NCRP data.
Breast cancer is not one disease — it is a family of conditions that differ in how they grow, what drives them, and how they respond to treatment. Triple negative breast cancer is defined by what it lacks: it tests negative for three receptors — oestrogen, progesterone, and HER2.
This matters because many breast cancer treatments work by blocking those receptors. Since TNBC does not have them, it cannot be treated with hormone-blocking therapy (anti-oestrogen medicines) or HER2-targeted agents. The treatment must instead focus on chemotherapy, immunotherapy, and surgery — with the specific combination decided by your tumor profile and stage.
TNBC accounts for roughly 10–15% of all breast cancer diagnoses. It is more common in women under 50 and in those with inherited changes in certain breast cancer susceptibility genes. It tends to grow and spread more quickly than hormone receptor-positive breast cancers, which is why early and expert assessment matters.
A diagnosis of TNBC can feel frightening. It is important to know that treatment has advanced considerably — and that with the right team, many patients with TNBC go on to live full lives. At CION, you walk this journey with a dedicated team, not alone.
TNBC has a higher rate of pathological complete response (pCR) to neoadjuvant chemotherapy than most other breast cancer subtypes. When chemotherapy is given before surgery and no residual cancer is found at the time of surgery, long-term outcomes are significantly better. This is why the sequence of treatment — and early specialist assessment — can be so important for TNBC patients. (Source: NCCN Breast Cancer Guidelines, 2024 edition)
Research has identified distinct molecular profiles within TNBC. Understanding your subtype helps your oncologist personalise your treatment approach.
The most frequently seen TNBC subtype. Tumour cells share features with the basal layer of breast tissue. Typically fast-growing. Responds well to chemotherapy-based treatment, and patients who achieve a complete response after neoadjuvant chemotherapy often have excellent outcomes.
This subtype shows a high presence of immune cells (tumour-infiltrating lymphocytes) within the tumour. It is more likely to respond to immunotherapy added to chemotherapy. Your oncologist will assess immune marker status when planning whether immunotherapy is appropriate for you.
A significant proportion of TNBC patients — particularly those diagnosed under 50 — carry an inherited change in a DNA-repair gene (such as BRCA1 or BRCA2). Identifying this is important because it can open additional targeted therapy options. It also has implications for close family members. Genetic counselling is available at CION.
These subtypes tend to show lower sensitivity to standard chemotherapy. They are more likely to need a tailored, evolving treatment approach. Careful pathology review and tumor board discussion ensures the right strategy is used from the outset, rather than waiting for a treatment to fail.
Your CION oncologist will explain which subtype your tumour is and what that means for your individual plan.
TNBC demands a team that moves quickly, thinks carefully, and keeps you informed at every step.
Every TNBC patient is reviewed by medical, surgical, and radiation oncologists together — not one doctor's opinion. The board meets regularly so your treatment decisions are made without delay.
Accurate staging is critical for TNBC. Our in-house PET-CT facility delivers expert-reviewed reports the same day, so staging is complete and the team can plan your treatment without a waiting gap.
CION is led by women — an important distinction for many breast cancer patients who want to be treated by a team that understands their journey at every level. We walk this journey with you, with compassion at the centre of everything we do.
You receive a written indicative cost estimate before any treatment begins — no surprise bills, no pressure. We accept Aarogyasri, CGHS, ECHS, EHS, and most private insurance schemes. EMI options are available.
You deserve to have every question answered. Every first consultation at CION is 45 minutes — unhurried. Your oncologist will review your reports, explain the diagnosis in plain language, and outline what to expect next. No rushed decisions.
Our 17 super-specialist oncologists bring over 150 years of combined oncology experience to every patient. TNBC is treated by oncologists who see it regularly — not once or twice a year. Deep familiarity with the condition leads to faster, more confident treatment decisions.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Meet a specialist who understands triple negative breast cancer. A 45-minute consultation, a clear plan, transparent costs. You deserve nothing less.
A precise diagnosis is the foundation of a precise treatment plan. Here is what the diagnostic journey looks like for a new TNBC patient at CION.
Your oncologist begins with a careful clinical examination and a review of any previous reports. A mammogram and breast ultrasound are the first imaging steps. For TNBC, an MRI is frequently added because it gives a clearer picture of tumour extent and checks the opposite breast.
A small sample of the tumour is taken using a core-needle biopsy — usually under local anaesthetic. The pathology laboratory examines the sample and tests for oestrogen receptors, progesterone receptors, and HER2. All three testing negative confirms a TNBC diagnosis. At CION, pathology slides are reviewed by specialist oncology pathologists.
Beyond the basic receptor testing, your oncologist may recommend further tumour profiling — including assessment of immune marker status (PD-L1) and testing for inherited gene variants. This additional information can significantly influence whether immunotherapy or targeted therapy is appropriate for your specific case.
Accurate staging determines whether the cancer remains localised or has spread to lymph nodes or other organs. CION provides same-day whole-body PET-CT reports, reviewed by specialist nuclear medicine physicians. This allows the tumor board to make staging-specific treatment decisions without delay.
Once all results are available, your case is presented to the full CION tumor board. Medical, surgical, and radiation oncologists review the findings together and agree on the most appropriate treatment sequence. You receive a written treatment plan and have a dedicated 45-minute consultation to go through it in full.
Treatment Approaches
TNBC treatment is always personalised. Your oncologist will explain which combination is right for you and in what order. No two patients receive exactly the same plan.
Chemotherapy is the primary systemic treatment for TNBC and is used in almost every case. It may be given before surgery (called neoadjuvant chemotherapy) to shrink the tumour and make surgery easier, or after surgery (adjuvant chemotherapy) to destroy any remaining cancer cells and reduce the risk of the cancer returning. When chemotherapy is given before surgery, your oncologist can see exactly how well your tumour is responding — and use that information to guide the next steps. Chemotherapy for TNBC typically runs in cycles over several months. Your team will monitor you closely throughout, managing side effects and adjusting the approach as needed.
Surgery removes the primary tumour from the breast and, when necessary, checks or removes nearby lymph nodes. For TNBC, the surgical plan is often decided after the response to neoadjuvant chemotherapy is known. If the tumour shrinks significantly, breast-conserving surgery (lumpectomy) may be possible even when the original tumour was large. If a mastectomy is needed, breast reconstruction options are discussed as part of the overall plan. The goal is always to remove all cancer with clear margins while preserving as much of the breast as is safe. Your surgical oncologist will walk you through the options specific to your case before any decision is made.
Radiation therapy uses precisely targeted beams of energy to destroy cancer cells that may remain in the breast or chest wall after surgery. It is recommended for most TNBC patients who have breast-conserving surgery, and for many who have mastectomy — particularly those with larger tumours or lymph node involvement. Radiation is delivered in short daily sessions over several weeks. Modern radiation techniques allow the treatment to be highly precise, reducing the dose to surrounding healthy tissue. CION radiation oncologists plan each course using imaging guidance to ensure the target receives the full dose while nearby organs — including the heart and lungs — are protected.
Immunotherapy works by helping your immune system recognise and attack cancer cells. For TNBC patients whose tumours express certain immune checkpoint markers (such as PD-L1), adding immunotherapy to chemotherapy has shown improved outcomes in clinical trials — particularly for earlier-stage TNBC. Whether immunotherapy is appropriate for you depends on your tumour's specific characteristics, which are tested as part of the diagnostic workup. Your medical oncologist will review the immune marker results and explain clearly whether immunotherapy is part of the recommended plan for your case. Immunotherapy is given by intravenous infusion, often on the same schedule as chemotherapy cycles.
A proportion of TNBC patients carry an inherited change in a DNA-repair gene. For this group, oral targeted therapy agents that exploit the cancer cell's DNA-repair deficiency can be an option, particularly in the setting of advanced or recurrent TNBC after initial treatment. Oral targeted therapy is generally easier to manage than intravenous treatments for many patients. Testing for the relevant gene variant is carried out as part of the diagnostic workup at CION. If targeted therapy is appropriate for you, your oncologist will discuss the evidence, the expected benefits, and the possible side effects in your consultation.
Treatment for TNBC is not only medical — it is also physical and emotional. CION's care team includes oncology nutritionists who help manage chemotherapy-related weight changes and energy levels, and psycho-oncologists who support patients and families through the emotional demands of a TNBC diagnosis. Studies show that patients who receive structured nutritional support during chemotherapy experience fewer treatment interruptions and maintain better quality of life. Post-treatment wellness planning — including follow-up imaging schedules, bone health monitoring, and fertility considerations for younger patients — is built into every TNBC care plan at CION.
Our oncologists answer questions about triple negative breast cancer treatment, surgery, and costs — with no pressure and full transparency.
These numbers reflect our entire breast cancer programme, which includes TNBC patients. They are published here because you deserve to make decisions based on real data.
CION's breast cancer 1-year survival rate is 96.9%, compared to the national average of 85.4% — a difference of 11.5 percentage points. This reflects the impact of early diagnosis, accurate staging, multi-disciplinary treatment planning, and consistent follow-up care across all breast cancer subtypes.
TNBC requires a particularly co-ordinated approach, and these outcomes reflect how seriously CION takes that co-ordination. Our tumor board model — where all three oncology disciplines review every case together — is central to achieving outcomes that exceed the national average.
*1-year survival. Source: ICMR/NCRP. CION outcomes data. These figures reflect the entire breast cancer programme across all subtypes and stages; individual patient outcomes vary based on stage at diagnosis, tumour biology, and treatment response.
Studies show that patients who achieve a pathological complete response (no cancer found at surgery after neoadjuvant chemotherapy) have significantly better long-term outcomes than those with residual disease. For TNBC patients in particular, achieving pCR is strongly associated with lower recurrence rates. This is one reason CION prioritises starting with accurate staging and prompt treatment — maximising the chance of a deep tumour response before surgery. (Source: NCCN, ESMO Breast Cancer Guidelines)
TNBC treatment cost varies because every patient's plan is different. The factors below affect the total indicative cost range. A written estimate is provided before any treatment begins.
Earlier-stage TNBC typically requires fewer treatment cycles and a shorter overall treatment duration. Advanced or metastatic TNBC may need longer courses of systemic treatment. Accurate staging with PET-CT at the outset means the estimate reflects the true extent of your disease.
Chemotherapy alone, surgery alone, or a combination of chemotherapy + surgery + radiation + immunotherapy will each have a different cost range. Adding immunotherapy or targeted therapy increases the total cost but may significantly improve outcomes for eligible patients. Your written estimate will itemise each component.
CION accepts Aarogyasri, CGHS, ECHS, EHS, and most private cashless insurance schemes. Our billing team will verify your coverage and explain what is covered and what out-of-pocket costs to expect before you start. EMI options are available for patients who need to spread the cost over time.
All cost figures at CION are indicative ranges only — never a single fixed number. A written estimate for your specific case is provided free of charge before any treatment begins.
Get Cost EstimationEvery patient's story is different. These are real people who came to CION facing a breast cancer diagnosis — and chose to take the first step.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.